Results 31 to 40 of about 12,210 (151)

Clinical research progress on ranibizumab in the treatment of retinopathy of prematurity

Shanghai Jiaotong Daxue xuebao. Yixue ban
Retinopathy of prematurity (ROP) is a retinal vascular proliferative fundus disease that occurs in premature infants with low birth weight. Currently, a widely used treatment is intravitreal injection of anti-vascular endothelial growth factor (VEGF ...
Chen Zhijun, Peng Jie, Zhang Xuerui, Zhao Peiquan   +3 more
doaj   +1 more source

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Cost Effectiveness and Resource Allocation, 2008
Background Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain.
Matthews Jane P, Hurley Susan F, Guymer Robyn H   +2 more
doaj   +1 more source

Adult‐onset Coats disease: A systematic review and meta‐analysis of imaging biomarkers and targeted therapies

Acta Ophthalmologica, EarlyView.
Abstract Coats disease diagnosed in adulthood is a rare idiopathic retinal telangiectatic vasculopathy that may differ in phenotype from childhood‐diagnosed cases. This systematic review synthesizes current evidence to characterize its clinical spectrum, imaging features, treatment outcomes and underlying mechanisms, with a focus on immunovascular ...
Catarina Francisco, Nisa Silva, Camiel J. F. Boon   +2 more
wiley   +1 more source

Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan

Ophthalmology and Therapy
Introduction This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient ...
Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Hiroshi Onishi, Junko Morii, Taiji Sakamoto   +6 more
doaj   +1 more source

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab

Indian Journal of Ophthalmology, 2015
Background: To investigate visual and anatomical outcomes in eyes with exudative age-related macular degeneration treated with intravitreal aflibercept following prior treatment with intravitreal ranibizumab.
Daniel Sanju Narayan, James Muecke
doaj   +1 more source

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration (RISE‐AMD): Safety data

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan, Celine Lee, Kaweh Daniel Zohalinejad, Mads Odgaard Mæng, Nanna Würtz Fabrin, Sigurrós Jónsdóttir, Anne Kjærsgaard Hassing, Søren Kveiborg Yde, Charles C. Wykoff, Henrik Vorum, Yousif Subhi, Marie Ørskov, Lasse Jørgensen Cehofski   +12 more
wiley   +1 more source

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

Acta Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider, Leyla Turan, Farah Arif, Jakob Bjerager, Oliver Niels Klefter, Carsten Faber, Yousif Subhi, Javad Nouri Hajari   +7 more
wiley   +1 more source

Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion

BMC Ophthalmology
Objective To compare the effectiveness and safety of three loading doses of bevacizumab and ranibizumab for macular edema (ME) due to branch retinal vein occlusion (BRVO). Methods This retrospective study included 49 patients with BRVO. The patients were
Sibel Coşkun Akdemir, Nurdan Gamze Taşlı   +1 more
doaj   +1 more source

Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema

Case Reports in Ophthalmology, 2015
Background/Aims: Bevacizumab and ranibizumab are routinely used to treat diabetic macular edema (DME). We aim to evaluate the usefulness of switching to ranibizumab therapy following bevacizumab treatment failure in eyes with DME. Methods: We performed a
Joel Hanhart, Itay Chowers
doaj   +1 more source

Impact of delayed appointments on treatment outcomes in neovascular macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola, Pekko Hujanen, Hannu Uusitalo, Hannele Uusitalo‐Järvinen   +3 more
wiley   +1 more source